Jeremy Crew

THE EXPERIENCE OF UK BLADDER CANCER PATIENTS DURING THE COVID-19 PANDEMIC: A SURVEY-BASED SNAPSHOT

R. Kockelbergh, R. Bryan, P. Harper, 2020, medRxiv.

Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study

K. Bensalah, J. Patard, H. Wallerand, 2011, Annals of Surgical Oncology.

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

A. Harris, S. Fuggle, M. Bradburn, 1997, Cancer research.

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

A. Harris, K. O'Byrne, T. Ganesan, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.

A. Harris, S. Fuggle, D. Cranston, 1999, The Journal of urology.